Global Graft-Versus-Host Disease (GVHD) Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Graft Versus Host Disease – Pipeline Review, H1 2015” to its store. The report provides an overview of the Graft Versus Host Disease’s therapeutic pipeline.

Graft Versus Host Disease Therapeutic Pipeline Review h1 2015

Graft Versus Host Disease Therapeutic Pipeline Review h1 2015

Past News Releases

RSS

The report “Graft Versus Host Disease – Pipeline Review, H1 2015” provides comparative analysis on the therapeutic development for Graft Versus Host Disease. Graft versus host disease occurs when the healthy stem cells from the donor have an immune response to the recipient’s cells. Chronic GVHD can cause permanent damage to tissues in the skin, connective tissue, glands and organs. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1 2015 pipeline review of nicotine addiction with 71 market data tables and 16 figures, spread across 302 pages is available at http://www.rnrmarketresearch.com/graft-versus-host-disease-gvhd-pipeline-review-h1-2015-market-report.html.

The report also reviews key players involved in the therapeutic development for Graft Versus Host Disease and special features on late-stage and discontinued projects. Companies discussed in this Graft Versus Host Disease – Pipeline Review, H1 2015 report include AbGenomics International, Inc., Adienne Pharma & Biotech, Alder Biopharmaceuticals Inc., Alexion Pharmaceuticals, Inc., Apceth GmbH & Co. KG, Athersys, Inc. , Bellicum Pharmaceuticals, Inc., Biogen Idec Inc., Dr. Falk Pharma GmbH, Enlivex Therapeutics Ltd, Escape Therapeutics, Inc., F. Hoffmann-La Roche Ltd., Generon (Shanghai) Corporation Ltd., Idera Pharmaceuticals, Inc., ImmuNext, Inc., Immunomedics, Inc., Jazz Pharmaceuticals plc, Kadmon Corporation, LLC, Kamada Ltd., Kymab Limited, Lycera Corp., Mesoblast Limited, Millennium Pharmaceuticals, Inc., MSM Protein Technologies, Inc., Neopharm Ltd., NeoStem, Inc., Novartis AG, Omni Bio Pharmaceutical Inc., Pharmacyclics, Inc., Pharmicell Co., Ltd., Pluristem Therapeutics Inc., R-Tech Ueno, Ltd., REGiMMUNE Corporation, Rigel Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Seattle Genetics, Inc., Sigmoid Pharma Limited, Soligenix, Inc., Spherium Biomed S.L., Targazyme, Inc., Therapix Biosciences Ltd, Tobira Therapeutics, Inc. and Xenikos B.V.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are AbGn-168H, aldesleukin, Alecmestencel-L, Alpha-1 Antitrypsin, alpha-1 proteinase inhibitor (human), ALXN-1007, anti-thymocyte globulin (rabbit), Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD, Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease, ApoCell, beclomethasone dipropionate, begelomab, bortezomib, BPX-501, brentuximab vedotin, budesonide, Bz-423, cannabidiol, Cell Therapy for Autoimmune Diseases and GVHD, Cell Therapy for Graft Versus Host Disease, Cell Therapy for GVHD, cenicriviroc mesylate, Cerecellgram for Graft Versus Host Disease, clazakizumab, Coversin, cyclosporine IR + cyclosporine CR, defibrotide, Drugs for Acute and Chronic GVHD, Drugs for Graft Versus Host Disease, erismodegib, F-652, Fc-Alpha-1 Antitrypsin, FcAAT-2, FcAAT-3, Ha-7, ibrutinib, ImmuneSafe, ImmuStem, IMO-8400, inolimomab, IT-603, IT-901, KD-025, KY-1005, milatuzumab, MSM-707, MultiStem, natalizumab, Oligonucleotide to Inhibit NFAT1 for GVHD, panobinostat, PLX-RAD, Protein to Activate TLR5 for Infectious Disease and GVHD, Recombinant HIV Gp120 Protein for GvHD And Autoimmune Disorders, Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease, remestemcel-L, RGI-2001, RO-2959, SP-12008, T-Guard and TZ-101. Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=365307. (This is a premium report priced at US$2000 for a single user License.)

List of Figures

Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2015 16
Number of Products under Development for Graft Versus Host Disease (GVHD) - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Products, H1 2015 26
Assessment by Monotherapy Products, H1 2015 76
Number of Products by Top 10 Targets, H1 2015 78
Number of Products by Stage and Top 10 Targets, H1 2015 78
Number of Products by Top 10 Mechanism of Actions, H1 2015 81
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 81
Number of Products by Top 10 Routes of Administration, H1 2015 84
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 85
Number of Products by Top 10 Molecule Types, H1 2015 86
Number of Products by Stage and Top 10 Molecule Types, H1 2015 87

Explore more reports on Therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@RnRMR
since: 06/2012
Follow >
RnR Market Research
Like >
Follow us on
Visit website